Rebound Pulmonary Hypertension After Nitric Oxide Withdrawal

산화질수(Nitric Oxide) 중단 후의 반동성폐고혈압

  • 이현우 (가천의과대학교 부석길병원 심장센터 흉부외과) ;
  • 이재웅 (가천의과대학교 부석길병원 심장센터 흉부외) ;
  • 현성열 (가천의과대학교 부석길병원 심장센터 흉부외과) ;
  • 박철현 (가천의과대학교 부석길병원 심장센터 흉부외) ;
  • 박국양 (가천의과대학교 부석길병원 심장센터 흉부외) ;
  • 이경천 (가천의과대학부속 길병원 마취과)
  • Published : 2000.02.01


Background: Inhaled nitric oxide therapy causes selective pulmonary vasodilation in congenital heart diseases with pulmonary hypertension. However discontinuation of inhaled nitric oxide therapy may be complicated by abrupt life-threatening rebound pulmonary hypertension(RPH) The purpose of this study was to prevent by comparing group I(without RPH n=13) and group II(with RPH n=6) to determine the risk factors involved inthe development of the RPH. Material and Method: Between Januarty 6, 1998 and April 14, 1999. we studied 19 consecutive children who were treated with inhaled nitric oxide for clinically significant pulmonary hypertension after an open heart surgery for congenital heart disease. the ratio of males and females was 12:7 ranging in age from 10 days to 6040 days(16 years) To identify the effects of nitric oxide between two groups we measured heart rate mean and systolic pulmonary arterial pressure mean and systolic systemic arterial pressure central venous pressure pH paO2/FiO2 and O2 saturation before and after the initiation and just before the withdrawal of the inhaled nitric oxide. result: In 6 of 19 patients(32%) withdrawal of inhaled nitric oxide caused RPH. In the two groups inhaled nitrix oxide decreased in pulmonary arterial pressure(PAP) without decreasing the systemic arterial pressure(SAP) and increased PaO2/FiO2 Compared with patients who had no RPH(group I) patients who had RPH(group II) were older in age (1204$\pm$1688 versus 546$\pm$1654 days p<0.05) received less nitric oxide therapy(34$\pm$18 versus 67$\pm$46 hours p<0.05) has shorter weaning process(5$\pm$3 versus 15一13 hours p<0.05) and received lowerconcentration of initial nitric oxide supply(11$\pm$8 versus 17$\pm$8 ppm p>0.05) and lower concentration just before the withdrawal nitric oxide(4.2$\pm$2.6 versus 5.6$\pm$2.6 ppm, p>0.05) Conclusion : We speculate that older age shorter of nitric oxide therapy shorter weaning process are the risk factors of RPH.



  1. Nature v.327 Nitric oxide release accounts for the biological activity of endothelium derived relaxing factor Palmer RMJ.;Ferrige AG.;Moncada SA.
  2. Lancet v.338 Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary vasodilation in pulmonary hypertension Peke-Zaba J.;Higenbattam TW.;Dihn-Xuxan AT.;et al.
  3. Anesthesiology v.77 Inhaled nitric oxide after mitral valve replacement in patients with chronic pulmonary artery hypertension Girard C.;Lehot JJ.;Pannetier JC.;Filley S.;Ffrench P.
  4. Ann Thorac Surg v.60 Inhaled nitric oxide for chidren with congenital heart disease and pulmonary hypertension Curran RD.;Mavroudis C.;Backer CL.;et al.
  5. Ann Thorac Surg v.60 Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operation Goldman AP.;Delius RE.;Deanfield JE.;et al.
  6. Ann Thorac Surg v.62 Nitric oxide might reduce the need for extracorporeal support in children with critical Godman AP.;Delius RE.;Deanfield JE.;et al.
  7. J. Thorac Cardiovasc Surg v.108 Very-low-dose inhaled nitric oxide;A selective pulmonary vasodilator after operation for congenital heart disease Miller OI.;Celermajer DS.;Deanfield JE.;et al.
  8. J.Thorac Cardiovasc Surg v.113 Cardiopulmonary bypass,myocardial management,and support techniques Fullerton DA.;Jaggers J.;Piedalue F.;et al.
  9. Ann Thorac Surg v.62 Rebound pulmonary hypertension after inhalation of nitric oxide Atz AM.;Adatia I.;Wessel DL.
  10. J.Thorac Cardiovasc Surg v.115 Dipylidamol attenuate rebound pulmonary hypertension after inhaled nitric oxide withdrawal in portoperative congenital heart disease Ivy DD.;Kinsella JP.;Ziegler JW.;Abman SH.
  11. Cric Res v.73 Negative feedback regulation of endothelial cell function by nitric oxide Buga GM.;Griscavage JM.;Rogers NE.;Ignarro LJ.
  12. Intensive Care Med v.22 The use of phosphodiesterase inhibitor(dipyridamole)to wean from inhaled nitric oxide Alaiyan SA.;Omran AA.;Dyer D.
  13. J.Thorac Cardiovasc Surg v.107 Inhaled nitric oxide as a therapy for pulmonary hypertension after operation for congenital heart defects Jounois D.;Pouard P.;Mauriat P.;et al.
  14. Arch Dis Child v.70 Guidlines for the safe administration of inhaled nitric oxide Miller OI.;Celermajer DS.;Deanfield JE.;Macrae DJ.
  15. Am J.Cardiol v.74 Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure Bocchi EA.;Bacal F.;Auler JOC.;de Carvalho MJ.;Bellotti G.;Pileggi F.
  16. Circulation v.87 Inhaled nitric oxide in congenital heart disease Robert JD.;Lang P.;Bigaltello LM.;Vlahakes GJ.;Zapol WM.
  17. Cardiol v.63 Recurrence of pulmonary hypertension after ventricular septal defect closure and perioperative response to nitric oxide Luciani GB.;Pessotto R.;Mazzucco A.
  18. An J.Crit Med v.153 Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure Lavoie A.;Hall LJ.;Olson DM.;Wylam ME.
  19. Acta Paediatr v.86 Life-threatening effects of discontinuing inhaled nitric oxide in children Cueto E.;Lopez-Herce J.;Sanchez A.;Carrillo A.
  20. J.Thorac Cradiovasc Surg v.107 Inhaled nitric oxide as a therapy for pulmonary hypertension after operation for congenital heart defects Journois D.;Pouard P.;Mauriat P.;et al.